Nosis Bio

Executive Summary

Nosis Bio, founded in 2021 and headquartered in San Diego, is a biotechnology company pioneering receptor-targeted RNA medicines. Its integrated platform combines physics-aware deep learning, single-cell biology, and high-throughput chemistry to address the fundamental challenge of cell-specific delivery for RNA therapeutics. By precisely targeting RNA payloads to diseased cells, Nosis aims to unlock the therapeutic potential of RNA for a broad range of chronic diseases, overcoming a key hurdle that has limited the field's clinical translation. The company's platform is designed to systematically identify optimal receptor-ligand pairs and engineer delivery vehicles, enabling a pipeline of novel RNA-based therapies with improved efficacy and reduced off-target effects. Nosis Bio operates at the intersection of artificial intelligence, drug delivery, and RNA biology, positioning itself to capture significant value in the rapidly growing RNA therapeutics market. The company's focus on extrahepatic delivery—a major unmet need—differentiates it from many competitors that rely on lipid nanoparticles for liver-targeted applications. With a strong scientific foundation and a computationally driven approach, Nosis has the potential to establish a versatile delivery platform applicable to multiple disease areas, including oncology, neurology, and genetic disorders. However, as an early-stage company, Nosis faces typical risks around platform validation, preclinical development, and financing, which will be key to its near-term trajectory.

Upcoming Catalysts (preview)

• Q4 2026Publication or presentation of preclinical in vivo data for lead delivery program70% success
• Q2 2026Completion of Series A financing round60% success
• TBDAnnouncement of a research collaboration with a pharmaceutical company40% success